In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function-Reference-Cited by-同舟云学术

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

Published:2009-04 Issue:4 Volume:19 Page:300-309
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Iulio Julia di,Fayet Aurélie,Arab-Alameddine Mona,Rotger Margalida,Lubomirov Rubin,Cavassini Matthias,Furrer Hansjakob,Günthard Huldrych F.,Colombo Sara,Csajka Chantal,Eap Chin B.,Decosterd Laurent A.,Telenti Amalio

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference35 articles.

1. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity;Ward;J Pharmacol Exp Ther,2003

2. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients;Marzolini;AIDS (London),2001

3. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients;Rotger;Pharmacogenet Genomics,2005

4. Genetic, Ethnic, and Gender Differences in the Pharmacokinetics of Antiretroviral Agents;Rotger;Curr HIV/AIDS Rep,2006

5. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals;Rotger;Clin Pharmacol Ther,2007

Cited by 134 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Physiologically-Based Pharmacokinetic Simulation to Evaluate Approaches to Mitigate Efavirenz-Induced Decrease in Levonorgestrel Exposure with a Contraceptive Implant;Pharmaceutics;2024-08-07

2. Genotyping, characterization, and imputation of known and novel CYP2A6 structural variants using SNP array data;Journal of Human Genetics;2023-04-14

3. Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia;CPT: Pharmacometrics & Systems Pharmacology;2023-03-23

4. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles;International Journal of Molecular Sciences;2023-02-08

5. Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS);Clinical Infectious Diseases;2021-11-19